**Comprehensive Medical Report**

**Patient Information:**

* Age: 35 years
* Sex: Female
* Premenopausal status: Yes
* BRCA mutation: Germline pathogenic BRCA1 mutation

**Medical History:**

* Recently diagnosed breast cancer (August 2016)
* Invasive ductal carcinoma, Nottingham grade 3 (of 3)
* Estrogen receptor (ER) positive (>75%)
* Progesterone receptor (PR) positive (1-10%)
* Human epidermal growth receptor 2 (HER2) positive (immunohistochemistry 2+, fluorescence in situ hybridization (FISH) positive for amplification)
* Metastatic disease to the brain (September 2017) and liver (February 2018)

**Treatment History:**

1. Neoadjuvant chemotherapy:
	* Paclitaxel, trastuzumab, and pertuzumab (September 2016)
	* Dose-dense doxorubicin, cyclophosphamide with neulasta support (January 2017)
2. Surgery:
	* Bilateral mastectomy with right axillary sentinel lymph node biopsy (April 2017)
3. Adjuvant therapy:
	* Trastuzumab with plans to continue 12 months of therapy along with tamoxifen (May 2017)
4. Metastatic treatment:
	* Ado-trastuzumab emtansine (October 2017)
	* Capecitabine/lapatinib (February 2018)
	* Pembrolizumab (March 2018) as part of a clinical trial
5. Procedures:
	* Gamma knife surgery for brain metastases (September 2017)
	* Bilateral salpingo-oophorectomy for prophylactic purposes (July 2017)

**Current Status:**

* Complete radiographic response to pembrolizumab therapy (June 2018)
* PD-L1 positive disease
* ER+, PR+, HER2+, PD-L1+ molecular features

**Clinical Trial Eligibility:**

* Prior therapies: THP-ddAC (residual disease), T-DM1, pembro (on trial)
* Procedures: Gamma knife to brain mets
* Sites of involvement: Brain, liver
* Molecular features: ER+, PR+, HER2+, PD-L1+

**Recommendations:**

* Continue pembrolizumab therapy
* Consider enrolling in clinical trials that target PD-L1 positive, ER+, PR+, HER2+ breast cancer
* Monitor for potential side effects and disease progression

This comprehensive medical report provides a detailed summary of the patient's medical history, treatment history, and current status. It highlights the patient's molecular features, prior therapies, and procedures, making it an essential document for other doctors to determine the best clinical trials for the patient.